Yoshiaki Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshiaki Ito has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Andre J van Wijnen
Molecular and Cell Biology and Oncology Research Institute, Institute of Molecular and Cell Biology, 30 Medical Drive, Singapore 117609, Singapore
1 shared publicationChohei Sakakura
1 shared publicationGang Huang
Laboratory of Cell Regulation, Department of Viral Oncology,Department of Genetics and Molecular Biology, Institute for Virus Research, Kyoto University, Shogoin, Sakyo‐ku, Kyoto, 606‐8507, Japan
1 shared publicationGary S Stein
Molecular and Cell Biology and Oncology Research Institute, Institute of Molecular and Cell Biology, 30 Medical Drive, Singapore 117609, Singapore
1 shared publicationHayao Nakanishi
1 shared publicationHee‐Jun Wee
Department of Viral Oncology, Kyoto University, Japan
1 shared publication
Latest Publications
- 24 May 2004
- Published by Springer Nature in Oncogene
- Vol. 23 (24) , 4209-4210
Nomenclature for Runt-related (RUNX) proteins
- 24 May 2004
- Published by Springer Nature in Oncogene
- Vol. 23 (24) , 4209-4210
Nomenclature for Runt-related (RUNX) proteins
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A287
Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines
- 30 April 2003
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , A287
Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines
- 1 February 2003
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 13 (1) , 43-47
RUNX transcription factors as key targets of TGF-β superfamily signaling
- 1 February 2003
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 13 (1) , 43-47
RUNX transcription factors as key targets of TGF-β superfamily signaling
- 25 November 2002
- Published by Springer Nature in Oncogene
- Vol. 21 (54) , 8351-8355
Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.
- 25 November 2002
- Published by Springer Nature in Oncogene
- Vol. 21 (54) , 8351-8355
Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.
- Open Access
- 1 October 2002
- Published by Springer Nature in EMBO Reports
- Vol. 3 (10) , 967-974
Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms
The RUNX family represents a small group of heterodimeric transcription factors that master‐regulate osteogenesis and hematopoiesis in mammals. Their genetic defects cause human diseases such as cleidocranial dysplasia (CCD) and acute myelogenous leukemia. However, the mechanism(s) regulating their functions are still poorly understood. Here, we report a novel observation that suggests that the osteogenesis‐associated homologue RUNX2 is negatively regulated by the phosphorylation of two conserved serines (S104 and S451) in two distinct functional aspects. The phosphorylation of S104 could abolish the heterodimerization of RUNX2 with the partner subunit, PEBP2β, which enhances the metabolic stability of RUNX2. On the other hand, the phosphorylation of S451 resides within the C‐terminal transcription inhibition domain of RUNX2 and hence is implicated in its functional mobilization. One CCD mutation, S104R of RUNX2, appears to mimic the phosphorylation‐dependent inhibition of heterodimerization, thereby rendering RUNX2 metabolically unstable.
- 1 October 2002
- Published by Springer Nature in EMBO Reports
- Vol. 3 (10) , 967-974
Open AccessSerine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms
The RUNX family represents a small group of heterodimeric transcription factors that master‐regulate osteogenesis and hematopoiesis in mammals. Their genetic defects cause human diseases such as cleidocranial dysplasia (CCD) and acute myelogenous leukemia. However, the mechanism(s) regulating their functions are still poorly understood. Here, we report a novel observation that suggests that the osteogenesis‐associated homologue RUNX2 is negatively regulated by the phosphorylation of two conserved serines (S104 and S451) in two distinct functional aspects. The phosphorylation of S104 could abolish the heterodimerization of RUNX2 with the partner subunit, PEBP2β, which enhances the metabolic stability of RUNX2. On the other hand, the phosphorylation of S451 resides within the C‐terminal transcription inhibition domain of RUNX2 and hence is implicated in its functional mobilization. One CCD mutation, S104R of RUNX2, appears to mimic the phosphorylation‐dependent inhibition of heterodimerization, thereby rendering RUNX2 metabolically unstable.